Compare FSK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSK | ABCL |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.5B |
| IPO Year | 2008 | 2020 |
| Metric | FSK | ABCL |
|---|---|---|
| Price | $11.11 | $13.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $12.05 | ★ $16.67 |
| AVG Volume (30 Days) | 1.4M | ★ 4.0M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 18.56% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $9.72 | $2.75 |
| 52 Week High | $16.31 | $14.98 |
| Indicator | FSK | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 73.83 |
| Support Level | $10.41 | $3.39 |
| Resistance Level | $11.22 | N/A |
| Average True Range (ATR) | 0.25 | 0.74 |
| MACD | -0.08 | 0.18 |
| Stochastic Oscillator | 20.77 | 92.13 |
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.